Ocular Therapeutix, Inc.

Incept, LLC

Civitas Therapeutics, Inc.

Charles D Blizzard

Peter K Jarrett

Rami El-Hayek

Michael Goldstein

Amarpreet S Sawhney

Timothy S Jarrett

Arthur Driscoll

Andrew Vanslette

Michael J McGrath

Andrew C Vanslette

Courtney A Rosales

Joseph Iacona

Erica Kahn

Ankita D Desai

Zachary Lattrell

Michael Bassett

Peter Jarrett

Michael M Lipp

Richard P Batycky

Mark A Tracy

Jean C Sung

Kevin L Ward

Blair C Jackson

Ernest E Penachio

Rachel Ryznal

Daniel Leblanc

Rebecca Martin

William Isom

Rami El-hayek

Rabia Gurses-ozden

Mark Ransbottom

Olivia Sherman

Elizabeth Braun

Chintan Patel

Michael J Mcgrath

Ankita Darshan Desai

Jeffrey D Mintzes

Lloyd P Johnston

Marie Elizabeth Chung

The invention relates to a sustained release biodegradable ocular implant containing axitinib dispersed in a hydrogel for the treatment of a retinal disease for an extended period of time.

Ocular implant containing a tyrosine kinase inhibitor

The invention relates to a sustained release biodegradable ocular implant containing a tyrosine kinase inhibitor dispersed in a hydrogel for the treatment of a retinal disease for an extended period of time.

The present invention relates to the treatment of ocular diseases in a human subject. In particular, the invention relates to an intracameral administration of a sustained release biodegradable intracameral implant.

Compositions and methods for treating ocular diseases

Methods of treating an eye for an ocular condition such as placing a composite depot comprising a xerogel with embedded degradable particles into an anterior chamber of an eye to deliver a therapeutic agent. The xerogel is a hydrogel after exposure to intraocular fluid and is degradable. The degradable particles comprise the therapeutic agent and hydrolytically degrade in the anterior chamber to provide a controlled release of the therapeutic agent into the eye. Materials and processes for making depots are provided as well as alternative methods of their use.

Intracameral drug delivery depots

Provided herein are sustained release biodegradable intracanalicular inserts comprising a hydrogel and an active agent, methods of treating or preventing an ocular disease in a subject in need thereof by administering such inserts as well as methods of manufacturing such inserts.

Sustained release biodegradable intracanalicular inserts comprising a hydrogel and an active agent

Provided herein are sustained release biodegradable intracanalicular insert comprising a hydrogel and cyclosporine, methods of treating or preventing an ocular disease in a subject in need thereof by administering such inserts as well as methods of manufacturing such inserts.

Sustained release biodegradable intracanalicular inserts comprising a hydrogel and cyclosporine

Drug delivery using bio-affecting drugs, particularly with shape changing drug delivery devices. Embodiments are included for depots for delivery of a therapeutic agent that change from an elongated state ex vivo to a coil in vivo where the agent is released.

Shape changing drug delivery devices and methods

The present invention relates to the treatment of ocular diseases in a human subject In particular, the invention relates to an intracameral administration of a sustained release biodegradable intracameral implant.

Methods of treating ocular diseases using polyalkylene glycol intracameral implants with polyactide travoprost particles

This invention relates to methods of treatment with a sustained release biodegradable ocular implant containing a tyrosine inhibitor dispersed in a hydrogel.

Methods of treatment with an ocular implant containing a tyrosine kinase inhibitor

Drug delivery involving hydrogels as used for various medical conditions, and includes hydrogels formed in an eye with extended drug release times. An embodiment of the invention is a method of delivering a therapeutic agent to a tissue comprising forming a hydrogel in situ in an eye with a therapeutic agent dispersed in the hydrogel, the agent having a low solubility in water. The agent may be essentially insoluble in water. The hydrogel may be made so that 50% to 100% w/w of the agent is released when the hydrogel is from 100% to 50% persistent, with the persistence being a measure of the dry weight of the hydrogel relative to an initial dry weight of the hydrogel.

Drug delivery from hydrogels

Growing community of inventors

Nashua, NH, United States of America

Charles D Blizzard